{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:33:13Z","timestamp":1786739593993,"version":"build-2736575974"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>This is the first report on a case of perindopril\/amlodipine-induced thrombotic microangiopathy (TMA) syndrome. A 48-year-old female was admitted complaining of nettle rash all over the body, bloody urine, and weakness shortly after starting antihypertensive therapy with perindopril\/amlodipine. Shortly thereafter, she developed pronounced hemiparesis, somnolence, and sensorimotor aphasia. Laboratory findings were compatible with microangiopathic hemolytic anemia and thrombocytopenia. She was diagnosed with TMA. Cessation of perindopril\/amlodipine therapy and treatment with plasma exchange and systemic corticosteroids resulted in full recovery. Very seldom perindopril\/amlodipine may cause hematologic abnormalities, probably through an immunological mechanism, but there were no reports of causing TMA so far. In our case, the symptoms began shortly after the start of perindopril\/amlodipine use. The clinical course of TMA in the case was compatible with TMA related to an acute, immune-mediated drug reaction. The most important thing is to promptly recognize TMA and its induction by a drug because distinctive treatment and cessation of the suspected drug can prevent severe outcome, as it was avoided in our patient.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/2452-2473.301915","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T03:21:04Z","timestamp":1606706464000},"page":"38-41","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Perindopril\/amlodipine-induced thrombotic microangiopathy"],"prefix":"10.4103","volume":"21","author":[{"given":"Vlatka","family":"Peri\u0161a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorian","family":"Laslo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Mari\u010di\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lada","family":"Zibar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20240909","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMra020528","article-title":"Thrombotic microangiopathies","volume":"347","author":"Moake","year":"2002","journal-title":"N Engl J Med"},{"key":"R2-8-20240909","first-page":"300","article-title":"Pathophysiology and management of thrombotic microangiopathies","volume":"11","author":"Ruggenenti","year":"1998","journal-title":"J Nephrol"},{"key":"R3-8-20240909","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1537-2995.2004.03412.x","article-title":"Tibor greenwalt award. The Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome registry: A program for patient care, education and research","volume":"44","author":"George","year":"2004","journal-title":"Transfusion"},{"key":"R4-8-20240909","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"R5-8-20240909","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: A systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"key":"R6-8-20240909","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.tjem.2016.08.002","article-title":"The evaluation of the audit of Fresh-Frozen Plasma (FFP) usage in emergency department","volume":"16","author":"Emektar","year":"2016","journal-title":"Turk J Emerg Med"},{"key":"R7-8-20240909","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1055\/s-2005-925474","article-title":"Drug-induced thrombotic microangiopathy","volume":"31","author":"Zakarija","year":"2005","journal-title":"Semin Thromb Hemost"},{"key":"R8-8-20240909","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00062752-200109000-00004","article-title":"Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome","volume":"8","author":"Medina","year":"2001","journal-title":"Curr Opin Hematol"},{"key":"R9-8-20240909","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood.V80.1.241.241","article-title":"Characterization of multiple quinine-dependent antibodies in a patient with episodic hemolytic uremic syndrome and immune agranulocytosis","volume":"80","author":"Stroncek","year":"1992","journal-title":"Blood"},{"key":"R10-8-20240909","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/0003-4819-119-3-199308010-00006","article-title":"Recurrent pancytopenia, coagulopathy, and renal failure associated with multiple quinine-dependent antibodies","volume":"119","author":"Maguire","year":"1993","journal-title":"Ann Intern Med"},{"key":"R11-8-20240909","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1182\/blood.V77.10.2190.2190","article-title":"Characterization of the binding domains on platelet glycoproteins Ib-IX and IIb\/IIIa complexes for the quinine\/quinidine-dependent antibodies","volume":"77","author":"Chong","year":"1991","journal-title":"Blood"},{"key":"R12-8-20240909","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"R13-8-20240909","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1345\/aph.19019","article-title":"Severe thrombocytopenia associated with amlodipine treatment","volume":"33","author":"salan","year":"1999","journal-title":"Ann Pharmacother"},{"key":"R14-8-20240909","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.0042-9007.2004.00376.x","article-title":"Amlodipine-induced immune sthrombocytopenia","volume":"86","author":"Garbe","year":"2004","journal-title":"Vox Sang"},{"key":"R15-8-20240909","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/jcpt.12051","article-title":"Simvastatin and amlodipine induced thrombocytopenia in the same patient: Double trouble and a literature review","volume":"38","author":"Cvetkovi\u0107","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"R16-8-20240909","first-page":"605","article-title":"Tolerance and safety of perindopril","volume":"11","author":"Santoni","year":"1989","journal-title":"Clin Exp Hypertens A"}],"container-title":["Turkish Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/2452-2473.301915","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:30:19Z","timestamp":1786735819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/2452-2473.301915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/2452-2473.301915","relation":{},"ISSN":["2452-2473"],"issn-type":[{"value":"2452-2473","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}